Revvity Launches EONIS Q System to Enhance Molecular Testing for Newborns

The EONIS Q workflow boasts a rapid turnaround time of approximately three hours from sample-in to result. Compared to traditional wet qPCR solutions, the system sets industry standards with advanced software capabilities.

Revvity has introduced the EONIS Q system, a CE-IVD declared platform designed to facilitate molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns. This platform is particularly relevant for laboratories in countries accepting the CE marking.

The urgency for immediate detection of SMA and SCID stems from the potential for positive outcomes through early intervention. If administered promptly, disease-modifying therapies for SMA and immunoglobulin treatments combined with stem cell therapies for SCID can significantly impact the prognosis.

However, the adoption of molecular testing for congenital disorders, including SMA and SCID, has been limited due to cost constraints and the technical expertise required.

The EONIS Q system aims to overcome these barriers by simplifying and streamlining molecular testing for SMA and SCID. The comprehensive workflow includes the EONIS Q96 instrument, the EONIS SCID-SMA kit, and the EONIS EASI software.

Petra Furu, general manager of reproductive health at Revvity, said, "Helping children get a healthier start to life is at the heart of our work and making molecular testing for inherited conditions like SMA and SCID more accessible can help further that aim. Without compromising quality, speed or test result accuracy, the EONIS Q system is designed to break down some of the common barriers that prevent newborn screening labs from adopting these tests."

The EONIS Q workflow boasts a rapid turnaround time of approximately three hours from sample-in to result. Compared to traditional wet qPCR solutions, the system sets industry standards with advanced software capabilities.

Notably, the workflow eliminates the need for wash steps, minimises pipetting and centrifuging, and reduces hands-on time, making it more efficient for laboratory professionals.

Resource and cost efficiencies are further optimised through the system's use of fewer consumables and one-time-use plasticware compared to other methods.

Revvity's EONIS Q system aligns with the startup's dedication to enhancing children's health outcomes by making molecular testing for inherited conditions more accessible without compromising on quality or accuracy.

This platform promises a significant leap forward in molecular testing, offering a valuable solution to healthcare providers and newborn screening labs seeking efficient, reliable, and cost-effective methods for early detection of genetic disorders in infants.

Established in 2023 and based in Massachusetts, USA, Revvity, Inc. is an American firm operating in the life sciences and diagnostics sector. The company is dedicated to serving the pharmaceutical and biotechnology industries, specifically emphasising offerings related to innovative developments in cell therapy and gene therapy approaches.